Further supporting the immune-enhancing role of CCL3, Yuan et al. [54] revealed that DC-targeting chemokines inhibit CRC progression and state that CCL3 exhibits anti-tumor activities in vivo. Here, CCL3 is linked to colorectal carcinoma.